Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects : Clinical Neuropharmacology

Journal Logo

Original Articles

Orally Disintegrating Selegiline in Parkinson Patients With Dopamine Agonist-Related Adverse Effects

Lyons, Kelly E. PhD*; Friedman, Joseph H. MD; Hermanowicz, Neal MD; Isaacson, Stuart H. MD§; Hauser, Robert A. MD; Hersh, Bonnie P. MD; Silver, Dee E. MD#; Tetrud, James W. MD**; Elmer, Lawrence W. MD††; Parashos, Sotirios A. MD, PhD‡‡; Struck, Lynn K. MD§§; Lew, Mark F. MD∥∥; Pahwa, Rajesh MD*

Author Information
Clinical Neuropharmacology 33(1):p 5-10, January 2010. | DOI: 10.1097/WNF.0b013e3181b7926f

Abstract

© 2010 Lippincott Williams & Wilkins, Inc.

You can read the full text of this article if you:

Access through Ovid